m
Recent Posts
Connect with:
Tuesday / August 16.
HomeminewsClinically Meaningful Five Year Hydrus Microstent Results

Clinically Meaningful Five Year Hydrus Microstent Results

Five year results have demonstrated that the Hydrus Microstent – a novel minimally invasive glaucoma surgery (MIGS) device – achieves sustained reduction in the need for invasive secondary glaucoma surgery and medication use, without any increased safety risk.

Roughly the size of an eyelash, the device was designed by Ivantis to lower eye pressure for open-angle glaucoma patients by reestablishing flow through Schlemm’s canal.

The five-year HORIZON data demonstrating the Hydrus Microstent’s clinically meaningful and statistically significant clinical benefits over the full five years, were presented at the 2021 American Glaucoma Society virtual meeting in March by Dr Iqbal ‘Ike’ Ahmed, Research Director at the Kensington Eye Institute and Director of the Glaucoma and Advanced Anterior Segment Surgery Fellowship Program at the University of Toronto.

“I think this is one of the most highly clinically relevant findings in any of the MIGS studies we’ve seen, further supporting the need and importance of combining patients who have cataract and glaucoma with a MIGS procedure,” Dr Ahmed said.

“As a clinician, I appreciate the effort made by Ivantis in following these HORIZON trial patients continuously out to five years. Safe, long-term durable outcomes are what we are looking for in any treatment,” he continued.

“One of the most important and noteworthy findings of this study is that, of the patients who went on to receive subsequent invasive surgery in the cataract-surgery-only arm, the majority were those who had what we would consider mild glaucoma at baseline. The lesson here is that it would be naïve for us to think that we can predict which patients will progress quickly. So I appreciate having evidence to show the value of a device like the Hydrus Microstent to use early on with my patients to effectively lower intraocular pressure (IOP), minimise the need to go on to further more invasive surgery, and prevent blindness.”

KEY FINDINGS

The HORIZON study included 556 patients with mild to moderate glaucoma treated in 38 centres in nine countries in North America, Europe and Asia. It was designed to demonstrate the safety and efficacy of the Hydrus Microstent for lowering IOP in glaucoma patients undergoing planned cataract surgery. Patients were randomised 2:1 to receive cataract surgery plus the Hydrus Microstent or cataract surgery alone, respectively.

The two-year results of the trial provided the foundation for United States Food and Drug Administration (FDA) approval of the Hydrus Microstent in August 2018. The five-year update demonstrates the long-term safety and durability of the benefits that were observed earlier:

  • 73% of ‘mild’ Hydrus Microstent patients (those on one glaucoma medication at baseline) remained medication-free at five years, compared with 48% in the cataract-surgery-alone arm. This represents the highest margin total of medication eliminations compared to a control group reported for any MIGS pivotal trial. There was a 20% to 30% improvement in the medication-free rate in the Hydrus group versus controls at all time points.
  • A 2.5% rate of subsequent invasive glaucoma surgery with the Hydrus Microstent, compared with 6.4% for cataract surgery alone. This equals a 2.8 times, or over 60%, reduction in the likelihood for requiring subsequent invasive glaucoma surgery and is a clinically meaningful and statistically significant difference.
  • The overall safety profile was similar for both groups. This includes continued stability of endothelial cell counts as well as rates of persistent inflammation (0.5% Hydrus vs. 2.1% cataract surgery alone).

“These new HORIZON data are important because patients, physicians and payors deserve to know if their MIGS devices will stand the test of time. These latest findings, coupled with the American Academy of Ophthalmology’s recent best-in-class grading of Hydrus Microstent in its 2020 Preferred Practice Pattern Treatment Guidelines, further validates that Ivantis is leading the way for evidence-based outcomes in the MIGS device space,” said Dave Van Meter, president and CEO of Ivantis.

In November 2020, the Hydrus Microstent received the highest combined grades for Level of Evidence, Quality of Supporting Body of Evidence, and Recommendation for Care of any MIGS device reviewed by the American Academy of Ophthalmology in its 2020 Preferred Practice Pattern Treatment Guidelines.

Reference 

1.Gedde SJ, Vinod K, Wright MM, Muir KW, Lind JT, Chen PP, Li T, Mansberger SL, on behalf of the American Academy of Ophthalmology Preferred Practice Pattern Glaucoma Panel, Primary Open-Angle Glaucoma Preferred Practice Pattern®. Ophthalmology. 2020. doi:10.1016/j.ophtha.2020.10.022 

DECLARATION

DISCLAIMER : THIS WEBSITE IS INTENDED FOR USE BY HEALTHCARE PROFESSIONALS ONLY.
By agreeing & continuing, you are declaring that you are a registered Healthcare professional with an appropriate registration. In order to view some areas of this website you will need to register and login.
If you are not a Healthcare professional do not continue.